Interleukin-17–targeted Treatment in patients with spondyloarthritis and associated cardiometabolic risk profile
Autor(es) y otros:
Fecha de publicación:
2023
Versión del editor:
Citación:
Frontiers in Immunology, 14, (2023); doi:10.3389/fimmu.2023.1203372
ISSN:
Patrocinado por:
This study received funding for publication from Novartis. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.
Ficheros en el ítem
Métricas
Compartir
Estadísticas de uso
Metadatos
Este ítem está sujeto a una licencia Creative Commons